Sector News

Mylan offers $28 billion for Perrigo

April 9, 2015
Life sciences
Mylan has made an offer to buy Dublin, Ireland-based Perrigo for more than $28 billion, as the current acquisitions trend in pharma continues at pace.
 
The company said it would pay $205 in a combination of cash and Mylan stock for each Perrigo share, which represents a greater than 25% premium to the latter’s stock price as of April 3, 2015.
 
According to Mylan, the marriage of these “highly complementary businesses” would create “a diversified, global pharmaceutical leader with an unmatched commercial and operating platform and a unique, one-of-a-kind profile”. 
 
In a letter to Perrigo’s chairman, Mylan chief Robert Coury noted that the proposed transaction “makes compelling strategic sense” and would result in a combined company with “a very strong financial profile”, with annual sales of more than $15 billion.
 
Perrigo confirmed receipt of the offer, and noted that its board will now meet to discuss the proposal.
 
Mylan’s move comes just months after it relocated its headquarters from the US to The Netherlands as part of its purchase of Abbott’s main branded generics business, thereby considerably cutting its tax bill.
 
By Selina McKee
 
Source: Pharma Times
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend